Study 01Completed
Adult mild TBI
Biomarker presence confirmed in TBI patients.
Traumatic brain injury · Point-of-injury diagnostics
Bring clarity
to brain injury.
ProbTBI® is a non-invasive, point-of-injury test that detects concussion and traumatic brain injury from a single body-fluid sample — read in minutes, as simply as a pregnancy test.
- 3studies
- Completed in Finland
- 151
- Participants across the studies
- 2014
- Founded in Turku, Finland
ProbTBI®
Cassette · LF-02SAMPLE PT-0241
Negative
No biomarker detected.
Funded by
US Dept. of DefenseEuropean UnionBusiness Finland
Clinical & research partners
Turku University HospitalSatasairaala (Pori Hospital)
The unmet need
Brain injury is still hard to detect.
TBI diagnosis and treatment are unmet needs in medicine — today there is no non-invasive, power-free, point-of-injury tool to detect a traumatic brain injury. Around 69 million new TBI cases occur annually, with up to 90% classified as mild. These "closed-head" injuries are frequently invisible, leaving many undiagnosed.
- 69M
- New TBI cases worldwide each year
- ~90%
- Of those injuries are mild TBI — and often go undiagnosed
- 0
- Non-invasive, power-free point-of-injury tests for TBI exist today
How ProbTBI® works
From injury to answer.
No imaging, no laboratory, no specialist. ProbTBI® brings an objective biomarker result to wherever the injury happens.
- 01
Collect
A non-invasive urine or saliva sample taken at the point of injury — no needle, no scanner.
- 02
Detect
A proprietary glycan biomarker captured by a lateral-flow assay.
- 03
Read
A clear positive or negative result appears in minutes — no instrument.
- 04
Act
Positive (injury indicated): escalate care immediately. Negative (no immediate injury detected): follow up and re-test if symptoms worsen.
ProbTBI® rapid test
A lab result, at the point of injury.
No imaging. No laboratory. No waiting. ProbTBI® puts an objective, biomarker-based answer in the hands of first responders, emergency teams, sports physicians and GPs.
- Non-invasive sample
- Urine or saliva sample — comfortable for adults and children alike.
- Result in minutes
- Point-of-injury read at the bedside or on the sideline.
- Simple to interpret
- Positive or negative — no training, no instrument required.
- Built on IP
- Protected by a portfolio of 7 patents. ProbTBI® trademarked.
Reading the result
Lateral-flow cassetteNo biomarker
Negative
No brain injury detected.
Biomarker present
Positive
Brain injury indicated — escalate care.
As easy to interpret as a pregnancy test — positive or negative, no instrument required.
Clinical evidence
Evaluated across three clinical studies.
Study 02Completed
Extended detection
Findings supported biomarker specificity to TBI.
Study 03Completed
Children & adolescents
Biomarker feasibility confirmed in a paediatric cohort.
“We have the opportunity to develop a portable, non-invasive test for quick detection of mild TBI and concussion — and thereby help patients and families who so desperately need it.”
Frequently asked
How is the sample collected?+
ProbTBI® uses a non-invasive urine or saliva sample taken at the point of injury — no blood draw, no imaging, suitable for adults and children.
How do I read the result?+
The cassette shows a positive or negative result within minutes, interpreted as simply as a pregnancy test. Positive indicates the presence of brain injury; negative means no injury detected.
Where is Medicortex based?+
Medicortex operates its R&D from PharmaCity, Turku, Finland — within Turku Science Park. Medicortex International AB (publ) is registered in Stockholm, Sweden.
What is the listing status?+
The reverse takeover completed on 30 June 2026: NGM's listing conditions were satisfied, the company was renamed from NOSIUM AB (publ) to Medicortex International AB (publ), and Dr. Adrian Harel was appointed CEO. The company acquired 89.9% of Medicortex Finland Oyj and its shares trade on NGM Growth Market under the ticker MEDFIN.
Corporate governance
Board, management & ownership.
Board of Directors
Anna Tenstam
Chair · Independent
MSc (Uppsala) and MBA (IMD Lausanne); 30+ years of leadership in pharmaceutical, medical-device and medical-aesthetics companies, with global CEO and chairman roles.
Dr. Adrian Harel
Founder & CEO · Board member
PhD in Neurobiology (Weizmann Institute) and MBA (University of Haifa); deep drug-development, GMP and manufacturing experience. Former CEO of BrainStorm Cell Therapeutics.
Nils Grönberg
Board member · Independent
30+ years in leadership across foundations and companies in the Turku region, with expertise in sales management, networks, investing and fundraising.
Ville Ranta-Panula
Board member · Independent
Globally networked drug- and business-development professional; currently Chief Commercial Officer at CRST Oy and a certified board member.
Jesper Yrwing
Board member
MSc in Economics (International Business), European Business School London; experienced business controller and CFO. Serves as the group's operational CFO.
Management team
Dr. Adrian Harel
Chief Executive Officer
Founder; a track record leading early-stage biotechnology companies through R&D and GMP.
Jesper Yrwing
Chief Financial Officer
Long experience as business controller and CFO. Board member and the group's operational CFO.
Dr. Lasse Välimaa
Chief Scientific Officer
PhD in Molecular Biotechnology & Diagnostics; Head of R&D since 2015, leading assay and detection development.
Pihla Miettinen
Chief Operating Officer
MSc in Human Neuroscience (Turku); oversees procurement, supplier relations, HR and public relations.
Largest shareholders
Aligned for the long term.
The founder holds a significant stake, aligning leadership with shareholder value. The full register is maintained at Euroclear.
- Dr. Adrian HarelFounder, CEO & board member6,291,397
- Other shareholders & free floatInstitutional & retail investorsBroadly held
Through the transaction the group acquired 89.9% of Medicortex Finland Oyj. Per-shareholder holdings shown here are indicative — refer to the company's information memorandum and the Euroclear register for exact figures.
Portfolio holdings
The listed vehicle's existing holdings.
Medicortex International AB (publ) — formerly NOSIUM AB (publ) — carries a portfolio of holdings from its venture-builder history. Combined book value is ≈ 14.4 MSEK. Figures per company filings.
Co-properties
Listed minority holding
- Capital
- 5.49%
- Votes
- 5.13%
- Book value
- 8.8 MSEK
Invest Riddarholmen 1802
Wholly-owned subsidiary
- Capital
- 100%
- Votes
- 100%
- Book value
- 5.1 MSEK
NOSIUM Consulting
Wholly-owned subsidiary
- Capital
- 100%
- Votes
- 100%
- Book value
- 0.32 MSEK
Dividend Sweden AB (publ)
Listed minority holding
- Capital
- 0.39%
- Votes
- 0.37%
- Book value
- 0.15 MSEK
News & events
Latest from Medicortex.
28 Sept 2026 · Regulatory
Medicortex CEO Adrian Harel: “Our goal is a brain injury test that works anywhere, for anyone, in minutes”
Medicortex International AB (publ) (NGM: MEDFIN) develops non-invasive tests for traumatic brain injury (TBI) and concussion, based on biomarkers in urine and saliva. The company’s lead product candidate, ProbTBI™, is a…
Read more1 Sept 2026 · Regulatory
Medicortex International AB (publ) enters into agreements ahead of planned directed set-off share issues totalling approximately SEK 9.9 million
Settlement of a loan, a fee for expanding the shareholder base, and a consultancy receivable through newly issued shares Medicortex International AB (publ) (“Medicortex” or “the Company”) announces today that the…
Read more31 Aug 2026 · Regulatory
Medicortex International AB (publ) offentliggör delårsrapport för perioden april–juni 2026
Inga jämförelsetal finns för koncernen Koncernen uppstod genom det omvända förvärvet av Medicortex Finland Oyj den 29 juni 2026 och existerade inte under 2025 – jämförelsesiffror saknas därför helt. Periodens resultat…
Read more31 Aug 2026 · Regulatory
Medicortex International AB (publ) publishes interim report for the period April–June 2026
No comparative figures available for the group. The Group came into existence through the reverse acquisition of Medicortex Finland Oyj on 29 June 2026 and did not exist during 2025 — comparative figures are therefore…
Read more
Heading towards a solution
Invest in the clarity patients deserve.
Medicortex International AB (publ) completed its reverse takeover on 30 June 2026 and trades on NGM Growth Market under MEDFIN. The group has raised EUR 8.4M, including three US Department of Defense grants, holds 10 patents, and is advancing ProbTBI® toward a TBI-diagnostics market forecast at USD 3.3bn by 2029. Certified Adviser: Nordic Certified Adviser AB.
- MEDFIN
- NGM Growth Market ticker · Medicortex International AB (publ)
- 89.9%
- of Medicortex Finland Oyj acquired by the group
- 3
- Clinical studies complete